

23. (New) A method as defined in claim 22, wherein said adverse immune response is an autoimmune disease or a graft rejection.

*Su*  
24. (New) A method as defined in claim 23, further comprising the step of co-administering an immunosuppressive drug.

*B1C2*  
25. (New) A method as defined in claim 24, wherein said immunosuppressive drug is selected from the group consisting of cyclosporin A, rapamycin and FK506.

*Confidential*  
26. (New) A method as defined in claim 21, which results into activated blood cells apoptosis.

27. (New) A method as defined in claim 21, which results into inhibition of energy and oxygen supply to said activated blood cells.

28. (New) A method as defined in claim 27, wherein said inhibition of energy and oxygen supply is caused by disrupting mitochondrial function in activated blood cells.

29. (New) A method as defined in claim 27, wherein said inhibition of energy and oxygen supply is caused by disruption of nitric acid synthesis.

30. (New) A method as defined in claim 21, wherein said proteasome inhibitor is lactocystein or an analog thereof.

*Su*  
*C3*  
31. (New) A method as defined in claim 24, wherein said proteasome inhibitor is lactocystein or an analog thereof.